The use of inhaled formoterol in the treatment of asthma

Annals of Allergy, Asthma and Immunology

Volumn 97, Issue 1, 2006, Pages 24-33

  Berger, William E ^a  

^a Allergy & Asthma Associates of Southern California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; DNA; FORMOTEROL; FORMOTEROL FUMARATE; PLACEBO; SALMETEROL; TERBUTALINE;

ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; GENETIC POLYMORPHISM; HEADACHE; HEART PALPITATION; HUMAN; LUNG FUNCTION; MEDLINE; METABOLIC DISORDER; NONHUMAN; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREMOR;

EID: 33746643743     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61365-8     Document Type: Article

References (88)

1. Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med. 1995;333:499-506.
2. Kelly HW, Murphy S. Beta-adrenergic agonists for acute, severe asthma. Ann Pharmacother. 1992;26:81-91.
3. Siegel D, Sheppard D, Gelb A, Weinberg PF. Aminophylline increases the toxicity but not the efficacy of an inhaled beta-adrenergic agonist in the treatment of acute exacerbations of asthma. Am Rev Respir Dis. 1985;132:283-286.
4. Godfrey S, König P. Inhibition of exercise-induced asthma by different pharmacological pathways. Thorax. 1976;31:137-143.
5. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 1997. NIH publication 97-4051.
6. National Asthma Education and Prevention Program Expert Panel report: guidelines for the diagnosis and management of asthma: update on selected topics-2002. J Asthma Clin Immunol. 2002;110(pt 2):S141-S219.
7. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Heart, Lung, and Blood Institute; 2002. NIH publication 02-3659.
8. 2-agonists. Implications for drug therapy. Drugs. 1994;47:207-222.
9. 2- adrenoceptor agonists in asthma management. Respir Med. 2005;99:152-170.
10. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J. 1994;7:569-578.
11. Palmqvist M, Ibsen T, Mellén A, Lötvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med. 1999;160:244-249.
12. van Noord JA, Smeets JJ, Raaijmakers JAM, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J. 1996;9:1684-1688.
13. Pauwels RA, Sears MR, Campbell M, et al, on behalf of the RELIEF Study Investigators. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J. 2003;22:787-794.
14. Pauwels RA, Löfdahl C-G, Postma DS, et al, for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337:1405-1411.
15. Barnes PJ. Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids. Respir Med. 2001;95(suppl B):S12-S16.
16. Grönneröd TA, von Berg A, Schwabe G, Soliman S. Formoterol via Turbuhaler® gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respir Med. 2000;94:661-667.
17. Bronsky EA, Yegen U, Yeh CM, et al. Formoterol provides long-lasting protection against exercise-induced bronchospasm. Ann Allergy Asthma Immunol. 2002;89:407-412.
18. Kemp JP, Dockhorn RJ, Busse WW, et al. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med. 1994;150(6 pt 1):1612-1615.
19. Decker N, Quennedey MC, Rouot B, et al. Effects of W-aralkyl substitution of β-agonists on α- and β-adrenoceptor subtypes: pharmacological studies and binding assays. J Pharm Pharmacol. 1982;34:107-112.
20. 3H]formoterol binding sites in lung: characterization and autoradiographic mapping. Eur J Pharmacol. 1994;269:35-41.
21. 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br J Pharmacol. 1994;113:687-692.
22. Erjefält I, Persson CGA. Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways. Am Rev Respir Dis. 1991;144:788-791.
23. Lindén A, Bergendal A, Ullman A, et al. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax. 1993;48:547-553.
24. Jeppsson A-B, Källström B-L, Waldeck B. Studies on the interaction between formoterol and salmeterol in guinea-pig trachea in vitro. Pharmacol Toxicol. 1992;71:272-277.
25. Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997;10:2484-2489.
26. Boonsawat W, Charoenratanakul S, Pothirat C, et al. Formoterol (OXIS®) Turbuhaler® as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med. 2003;97:1067-1074.
27. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax. 1992;47:30-33.
28. Seberová E, Andersson A. Oxis® (formoterol given by Turbuhaler®) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med. 2000;94:607-611.
29. Wegener T, Hedenström H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest. 1992;102:535-538.
30. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2000;56:1054-1070.
31. 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993;8:334-339.
32. 2-adrenergic receptor in nocturnal and nonnocturnal asthma: evidence that GIy 16 correlates with the nocturnal phenotype. J Clin Invest. 1995;95:1635-1641.
33. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 1997;100:3184-3188.
34. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364:1505-1512.
35. Clinical Trials.gov. Long-acting beta agonist response by genotype (large). Available at: http://www.clinicaltrials.gov/ct/show/NCT00200967. Accessed December 2, 2005.
36. 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet. 1995;345:1213-1214.
37. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 1993;268:23116-23121.
38. 2-adrenoceptor on the effects of β-adrenoceptor agonists on human lung mast cells. Int Immunopharmacol. 2003;3:91-95.
39. 2-adrenergic receptor regulate receptor expression. J Clin Invest. 1998;102:1927-1932.
40. 2-adrenoceptor polymorphism. Chest. 2000;118:321-328.
41. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Heart, Lung, and Blood Institute; 2003. NIH publication 02-3659. Management Segment (Chapter 7). Updated 2003 from the 2002 document.
42. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in non-steroid-dependent asthmatics. Am Rev Respir Dis. 1990;142:832-836.
43. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343:332-336.
44. Pauwels RA, Pedersen S, Busse WW, et al, on behalf of the START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071-1076.
45. Busse W, Raphael GD, Galant S, et al, for the Fluticasone Propionate Clinical Research Study Group. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol. 2001;107:461-468.
46. Fahy JV, Boushey HA. Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation. Eur Respir J. 1998;11:1240-1247.
47. Bensch G, Berger WE, Blokhin BM, et al, on behalf of the International Study Group on Foradil Evaluation in Pediatric Asthma. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol. 2002;89:180-190.
48. Akpinarli A, Tuncer A, Saraçlar Y, et al. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Arch Dis Child. 1999;81:45-48.
49. Pearlman DS, Kottakis J, Till D, Cioppa GD. Formoterol delivered via a dry powder inhaler (Aerolizer): results from long-term clinical trials in children. Curr Med Res Opin. 2002;18:445-455.
50. Pohunek P, Matulka M, Rybmcek O. Dose-related efficacy and safety of formoterol (Oxis®) Turbuhaler® compared with salmeterol Diskhaler® in children with asthma. Pediatr Allergy Immunol. 2004;15:32-39.
51. Häcki MA, Hinz GW, Medici TC. Clinical experience over five years of daily therapy with formoterol in patients with bronchial asthma. Clin Drug Invest. 1997;14:165-174.
52. Kesten S, Chapman KR, Broder I, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis. 1991;144:622-625.
53. Steffensen I, Faurschou P, Riska H, et al. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease: a 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol. Allergy. 1995;50:657-663.
54. Kesten S, Chapman KR, Broder I, et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy. 1992;69:415-420.
55. Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J. 2001;18:262-268.
56. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8 pt 1):1392-1397.
57. Kips JC, O'Connor BJ, Inman MD, et al. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med. 2000;161:996-1001.
58. Zimmerman B, D'Urzo A, Bérubé D. Efficacy and safety of formoterol Turbuhaler® when added to inhaled corticosteroid treatment in children with asthma. Pediatr Pulmonol. 2004;37:122-127.
59. Andersson F, Ståhl E, Barnes PJ, et al, for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Adding formoterol to budesonide in moderate asthma-health economic results from the FACET study. Respir Med. 2001;95:505-512.
60. Kelsen SG, Church NL, Gillman SA, et al. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J Asthma. 1999;36:703-715.
61. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368-1373.
62. Tattersfield AE, Löfdahl C-G, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet. 2001;357:257-261.
63. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129-136.
64. Oxis [prescribing information]. Lund, Sweden: AstraZeneca PLC; 2004.
65. Shapiro GS, Yegen U, Xiang J, et al. A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol. Clin Ther. 2002;24:2077-2087.
66. Patessio A, Podda A, Caone M, et al. Protective effect and duration of action of formoterol aerosol on exercise-induced asthma. Eur Respir J. 1991;4:296-300.
67. Boner AL, Spezia E, Piovesan P, et al. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med. 1994;149(4 Pt 1):935-939.
68. Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol. 1992;89:1176-1182.
69. 2-adrenergic agonist. Respir Med. 1990;84:293-295.
70. Ferrari M, Segattini C, Zanon R, et al. Comparison of the protective effect of formoterol and of salmeterol against exercise-induced bronchospasm when given immediately before a cycloergometric test. Respiration. 2002;69:509-512.
71. Richter K, Janicki S, Jörres RA, Magnussen H. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur Respir J. 2002;19:865-871.
72. 2-agonists in management of childhood asthma: a critical review of the literature. Pediatr Pulmonol. 2000;29:221-234.
73. Abramson MJ, Walters J, Walters EH. Adverse effects of β-agonists: are they clinically relevant? Am J Respir Med. 2003;2:287-297.
74. Malolepszy J, Böszörményi Nagy G, Selroos O, et al. Safety of formoterol Turbuhaler® at cumulative dose of 90 μg in patients with acute bronchial obstruction. Eur Respir J. 2001;18:928-934.
75. Tötterman KJ, Huhti L, Sautinen E, et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler® for 3 days in stable asthmatic patients. Eur Respir J. 1998;12:573-579.
76. Maesen FPV, Costongs R, Smeets JJ, et al. The Effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest. 1991;99:1367-1373.
77. Guhan AR, Cooper S, Oborne J, et al. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax. 2000;55:650-656.
78. Ind PW, Villasante C, Shiner RJ, et al. Safety of formoterol by Turbuhaler® as reliever medication compared with terbutaline in moderate asthma. Eur Respir J. 2002;20:859-866.
79. Wilton LV, Shakir SA. A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England. Drug Saf. 2002;25:213-223.
80. Fitzgerald JM, Chapman KR, Cioppa GD, et al, and the Canadian FO-OD1 Study Group. Sustained bronchoprotection, bronchodilation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol. 1999;103:427-435.
81. Hancox RJ, Taylor DR. Long-acting β-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids. BioDrugs. 2001;15:11-24.
82. Kozlik-Feldmann R, von Berg A, Berdel D, Reinhardt D. Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma. Eur J Med Res. 1996;1:465-470.
83. Ekström T, Ringdal N, Tukiainen P, et al. A 3-month comparison of formoterol with terbutaline via Turbuhaler: a placebo-controlled study. Ann Allergy Asthma Immunol. 1998;81:225-230.
84. Ekström T, Ringdal N, Sobradillo V, et al. Low-dose formoterol Turbuhaler® (Oxis®) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.). Respir Med. 1998;92:1040-1045.
85. Lipworth B, Tan S, Devlin M, et al. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med. 1998;104:431-438.
86. Davis BE, Reid JK, Cockcroft DW. Formoterol thrice weekly does not result in the development of tolerance to bronchoprotection. Can Respir J. 2003;10:23-26.
87. Simons FE, Gerstner TV, Chang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics. 1997;99:655-659.
88. Nelson J, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med. 1998;339:141-146.